# Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

> **NCT04798430** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **LIB Therapeutics LLC** · enrollment: 2000 (estimated)

## Conditions studied

- Cardiovascular Disease With Mention of Arteriosclerosis
- Elevated Cholesterol
- Familial Hypercholesterolemia

## Interventions

- **DRUG:** lerodalcibep

## Key facts

- **NCT ID:** NCT04798430
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-12-03
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04798430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04798430, "Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04798430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*